Biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products.
MannKind Corporation, a leading biopharmaceutical firm based in Westlake Village, California, specializes in advancing and commercializing innovative inhaled therapeutic products tailored for endocrine disorders and rare lung diseases across the United States. One of its flagship offerings is Afrezza, an inhaled insulin designed to enhance glycemic control in adults grappling with diabetes. This breakthrough product provides a non-invasive alternative to traditional insulin injections.
In addition to Afrezza, MannKind markets Thyquidity, aimed at treating hypothyroidism, and actively collaborates with adult and pediatric endocrinologists, as well as other healthcare professionals, to expand treatment options for this condition. The company continues to innovate through strategic partnerships, including a notable license and collaboration agreement with United Therapeutics Corporation.
Furthermore, MannKind has entered into a significant agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide. This partnership aims to leverage aviptadil's potential in protecting cells from inflammatory conditions, contributing to the company's diverse therapeutic portfolio.
Established in 1991, MannKind Corporation remains at the forefront of biopharmaceutical innovation, dedicated to advancing therapeutic solutions that improve patient outcomes and quality of life. With a steadfast commitment to research and development, MannKind continues to drive forward in its mission to address unmet medical needs in the field of endocrinology and beyond.